文献速递白血病淋巴瘤

达沙替尼与帕纳替尼治疗T细胞急性淋巴细胞白血病的临床前药代动力学与药效学评价

Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2023-04-19

在51例人T-ALL样本中,达沙替尼与帕纳替尼对LCK激活的T-ALL显示相似的细胞毒活性,帕纳替尼略强。小鼠口服帕纳替尼清除较慢、Tmax较长、AUC0-24h较高,但最大pLCK抑制相当。模拟显示达沙替尼140mg与帕纳替尼45mg每日一次均足以实现>50% pLCK抑制。

要点

  • 51例人T-ALL中达沙替尼与帕纳替尼细胞毒活性模式相似,帕纳替尼略强。
  • 小鼠口服帕纳替尼清除较慢、Tmax较长、AUC0-24h较高,最大pLCK抑制相当。
  • 模拟稳态下达沙替尼140mg与帕纳替尼45mg每日一次均足以实现>50% pLCK抑制。

核心结论

  • 本文描述了达沙替尼和帕纳替尼作为LCK抑制剂在T-ALL中的药代动力学和药效学特征,为这些药物的人体试验开发提供了关键数据。

研究设计与样本

  • 临床前药代动力学与药效学评价研究,纳入51例人T-ALL病例,并在小鼠中口服给药。

主要发现

  • 在51例人T-ALL病例中,达沙替尼与帕纳替尼显示相似的细胞毒活性模式,帕纳替尼略强。
  • 小鼠口服给药时,帕纳替尼清除较慢、Tmax较长、AUC0-24h较高,但两药最大pLCK抑制相当。
  • 模拟稳态下,达沙替尼140mg每日一次和帕纳替尼45mg每日一次分别足以实现>50% pLCK抑制13.0和13.9小时/天,与这些药物在BCR::ABL1白血病中的药效学特征相当。
  • 建立了携带LCK T316I突变的达沙替尼耐药T-ALL细胞系模型,帕纳替尼在该模型中保留对LCK的部分活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

LCK is a novel therapeutic target in ~40% of T-cell acute lymphoblastic leukemia (T-ALL), and dasatinib and ponatinib can act as LCK inhibitors with therapeutic effects. We herein report a comprehensive preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib in LCK-activated T-ALL. In 51 human T-ALL cases, these two drugs showed similar patterns of cytotoxic activity, with ponatinib being slightly more potent. Given orally in mice, ponatinib was associated with slower clearance with a longer Tmax and higher AUC0-24 h, although maximum pLCK inhibition was comparable between the two drugs. After establishing the exposure-to-response models, we simulated the steady-state pLCK inhibitory effects of each drug at currently approved dosages in humans: dasatinib at 140 mg and ponatinib at 45 mg once daily are both sufficient to achieve >50% pLCK inhibition for 13.0 and 13.9 h/day, respectively, comparable to pharmacodynamic profiles of these agents in BCR::ABL1 leukemias. Moreover, we developed a dasatinib-resistant T-ALL cell line model with LCK T316I mutation, in which ponatinib retained partial activity against LCK. In conclusion, we described the pharmacokinetic and pharmacodynamic profiles of dasatinib and ponatinib as LCK inhibitors in T-ALL, providing critical data for the development of human trials of these agents.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yoshimura S, Panetta JC, Hu J, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023. PMID: 37076694. doi:10.1038/s41375-023-01900-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。